Michiel Van der Heijden
Systemic Therapy for bladder cancer
Systemic treatment for bladder cancer patients has evolved in recent years, giving patients more therapeutic options. We aim to advance the development of a personalized approach to bladder cancer by exploring and targeting the tumor-immune microenvironment and finding biomarkers that can guide systemic therapy. Our key focus is on the neoadjuvant setting, as the highest gains in cure rates can be achieved here and new therapies enable bladder sparing approaches in more patients. Through the large number of bladder cancer patients, excellent multidisciplinary collaboration and broad availability of clinical trials with novel therapeutics at the NKI/AVL, discoveries can rapidly be translated into clinical trials.
The Van der Heijden group also studies penile cancer, which is a rare cancer, by conducting clinical trials with immunotherapy, translational research through the RADAR consortium and contributing to international clinical guidelines.
More about this group
Our research
Publications of this group
Contact our group